Clinical Trial Update: Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating inhaled iloprost for persistent pulmonary hypertension in term and near-term infants has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Pulmonary Hypertension of the Newborn

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: University of Chicago | Conditions: Pulmonary Hypertension | Phase 4 | Status: TERMINATED